MedTrace Logo

Non-Damaging Photothermal Therapy of Non-exudative Age Related Macular Degeneration

NCT02569892 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

This is a randomized controlled study of non-damaging photothermal macular grid laser versus sham laser therapy in patients with dry age-related macular degeneration (AMD) and large high-risk drusen. The goal of the study is to determine if this treatment will reduce macular drusen volume and also whether this might improve visual acuity or reduce the risk of conversion to advanced age-related macular degeneration defined as development of choroidal neovascularization or geographic atrophy.

Conditions

  • Macular Degeneration
  • Retinal Drusen

Interventions

DEVICE

Pascal Retinal Laser Photocoagulator

Sub-threshold macular laser treatment with Pascal laser Endpoint Management System

Sponsors & Collaborators

Principal Investigators

  • Steven Sanislo, MD · Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2020-02-01
Completion
2021-01-25

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569892 on ClinicalTrials.gov